3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
22
Colorectal Neoplasms
19
Pancreatic Neoplasms
15
Stomach Neoplasms
14
Rectal Neoplasms
10
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Esophageal Squamous Cell Carcinoma
7
Esophageal Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Locally Advanced Rectal Cancer
6
Carcinoma, Non-Small-Cell Lung
6
Liver Neoplasms
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Sarcoma
4
Melanoma
4
Lung Neoplasms
4
Gastrointestinal Stromal Tumors
4
Endometrial Neoplasms
4
Colonic Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Neoplasms
2
Mesothelioma
2
Interventions
Paclitaxel
11
Fluorouracil
10
pembrolizumab
9
Cisplatin
9
Radiotherapy
7
Carboplatin
6
Esophagectomy
5
Nivolumab
4
Drug Therapy
4
Radiotherapy, Intensity-Modulated
3
Leucovorin
3
Chemoradiotherapy
3
Cetuximab
3
Capecitabine
3
durvalumab
2
atezolizumab
2
Oxaliplatin
2
Ipilimumab
2
spartalizumab
1
sintilimab
1
selinexor
1
regorafenib
1
prexasertib
1
osimertinib
1
niraparib
1
nilotinib
1
nedaplatin
1
nanocis
1
fludarabine
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
spartalizumab
×
Gastrointestinal
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts